Product Description
We report that AKN-028, a novel tyrosine kinase inhibitor (TKI), is a potent FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor (IC(50)=6 nM), causing dose-dependent inhibition of FLT3 autophosphorylation. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22864397/)
Mechanisms of Action: Global Transcription Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Akinion AB
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01573247 |
AKN001 | P2 |
Terminated |
Acute Myeloid Leukemia |
2016-03-01 |
2019-03-19 |
Treatments |
|
2011-003285-33 |
2011-003285-33 | P2 |
Terminated |
Acute Myeloid Leukemia |
2012-11-02 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|